A Randomized Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine With Our Without a PD-1 Blockade Antibody (Nivolumab) for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas

Trial Profile

A Randomized Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine With Our Without a PD-1 Blockade Antibody (Nivolumab) for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Tumour cell vaccine-GVAX (Primary) ; Cyclophosphamide; Nivolumab
  • Indications Pancreatic cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 01 Dec 2015 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018 as per ClinicalTrials.gov record.
    • 01 Dec 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Feb 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top